1. Denmark Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
Novonesis A/S Class B

Novonesis A/S Class B

63.42
EUR
-0.64
(-1.00%)
25.88BMarket Cap
Nov 05Next Earn
Novonesis A/S Class B
TG:NZM2
(Tradegate Exchange)

Recent

price

63.42

P/E

ratio

- -

div

yld

0.90%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.56
0.6
0.64
0.67
0.72
0.82
0.85
0.89
0.89
0.9
0.9
0.97
1.14
8.67
8.38
8.92
- -
Revenue per Share
0.09
0.11
0.12
0.13
0.15
0.17
0.18
0.19
0.2
0.2
0.18
0.2
0.24
1.47
0.67
1.25
- -
Basic EPS, GAAP
0.06
0.08
0.09
0.1
0.22
0.14
0.16
0.14
0.14
0.14
0.22
0.18
0.07
1.02
1.44
1.61
- -
Free Cash Flow per Basic Share
0.02
0.03
0.03
0.04
0.05
0.05
0.06
0.07
0.08
0.09
0.1
0.1
0.1
1.38
0.55
0.86
0.57
Dividend per Share
0.45
0.51
0.55
0.76
0.8
0.69
0.71
0.69
0.71
0.73
0.73
0.77
0.9
6.76
23.98
23.3
23.92
Book Value per Share
0.39
0.38
0.4
0.56
0.59
0.53
0.55
0.54
0.58
0.61
0.56
0.44
0.6
4.57
2.47
-0.5
0.08
Tangible Book Value per Share
313
315
314
314
312
306
300
295
290
285
280
278
277
277
458
466
465
Basic Weighted Avg Shares
175
191
202
211
225
252
256
262
258
257
253
270
317
2,402
3,834
4,158
- -
Sales/Revenue/Turnover
21.77
22.08
24.43
24.7
25.26
27.74
27.9
28.31
28.28
24.66
25.76
25.98
25.23
25.43
17.19
21.23
- -
Operating Margin (%)
- -
14
13
13
16
17
18
19
20
21
23
25
26
186
544
575
- -
Depreciation Expense
29
33
36
40
46
51
55
56
58
56
51
57
66
406
306
584
- -
Net Income, GAAP
23.98
24.31
21.98
20.22
22.99
21.98
21.41
19.5
18.01
16.95
19.74
19.85
19.1
22.26
26.68
21.5
- -
Effective Tax Rate (%)
16.6
17.37
17.94
18.73
20.27
20.16
21.57
21.46
22.42
21.94
20.16
21.04
20.94
16.9
7.98
14.04
- -
Profit Margin (%)
54
44
35
58
61
51
51
28
24
41
50
39
41
297
791
-758
884
Working Capital
- -
27
31
30
22
22
31
24
26
58
66
73
71
612
1,530
- -
2,831
LT Debt
141
160
172
199
203
208
212
203
205
206
203
221
257
1,926
11,176
10,855
11,155
Total Equity
23.19
19.44
19.31
18.67
19.81
22.95
23.16
23.58
23.03
22.16
19.41
18.95
18.71
28.33
6.05
5.78
- -
Return on Invested Capital (%)
24.77
20.75
18.75
18.48
19.87
21.89
23.35
23.16
22.86
21.79
19.32
19.35
18.97
25.23
4.54
5.35
- -
Return on Capital (%)
23.6
22.03
21.85
21.35
22.67
24.67
26.25
27.11
28.37
27.53
24.99
27.31
28.62
38.2
4.69
5.3
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
289
237
LT Borrowings
- -
2,923
2,831
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
466
466
466
Market Capitalization
25,513
24,244
25,877

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,983
2,046
2,081
Cash, Cash Equivalents & STI
296
329
314
Accounts Receivable, Net
717
756
792
Inventories
772
793
836
Total Current Liabilities
2,741
1,222
1,197
Payables & Accruals
- -
- -
- -
ST Debt
- -
289
237
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
115.02%
230.51%
-2.87%
Free Cash Flow
142.05%
273.49%
13.73%
Net Income, GAAP
60.78%
121.24%
90.84%
Sales/Revenue/Turnover
75.11%
150.09%
8.45%
Total Cash Common Dividend
137.21%
264.34%
61.21%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
854
978
- -
981
3,834
2025
1,078
1,019
- -
997
4,158
2026
1,119
1,116
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.06
- -
0.19
0.67
2025
0.4
0.29
- -
0.26
1.25
2026
0.43
0.37
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.24
- -
- -
0.55
2025
- -
0.56
- -
- -
0.86
2026
0.57
- -
- -
- -
- -
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Novonesis A/S (formerly Novozymes A/S) develops and produces industrial enzymes, microorganisms, biopharmaceutical ingredients, and biosolutions for multiple sectors including agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile, and wastewater treatment; core offerings encompass lipases, proteases, oxidoreductases, carbohydrases, and specialized enzymes for dairy, baking, beverages, meat, plant-based foods, and functional nutrition, alongside probiotics, biopolymers, and proteins serving over 40 industries globally. Founded in 2000 as a spin-off from Novo Nordisk with roots tracing to 1925, the company is headquartered in Bagsværd, Denmark, and maintains production and R&D facilities across more than 140 countries, including the United States, China, Brazil, India, and the United Kingdom. In January 2024, Novozymes merged with Chr. Hansen in a statutory combination approved by regulators to form Novonesis, creating a global biosolutions leader with projected 6-8% organic sales growth through 2025, EUR 200 million in revenue synergies, and enhanced capabilities in biological innovation for sustainable applications.

Company News

Company News APIChatGPT

  • defenseworld.net

    Novozymes A/S (OTCMKTS:NVZMF) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

  • defenseworld.net

    Financial Analysis: Novozymes A/S (OTCMKTS:NVZMY) vs. Neo Performance Materials (OTCMKTS:NOPMF)

  • zacks.com

    FUL or NVZMY: Which Is the Better Value Stock Right Now?

  • seekingalpha.com

    Novozymes A/S (NVZMY) Q2 2026 Earnings Call Transcript

  • zacks.com

    FUL vs. NVZMY: Which Stock Is the Better Value Option?

  • zacks.com

    FUL or NVZMY: Which Is the Better Value Stock Right Now?

  • zacks.com

    FUL or NVZMY: Which Is the Better Value Stock Right Now?

  • zacks.com

    FUL vs. NVZMY: Which Stock Should Value Investors Buy Now?

  • zacks.com

    FUL or NVZMY: Which Is the Better Value Stock Right Now?

  • defenseworld.net

    Analyzing Novozymes A/S (OTCMKTS:NVZMY) & Orion (NYSE:OEC)

  • seekingalpha.com

    Novozymes A/S (NVZMY) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    Novozymes A/S (OTCMKTS:NVZMF) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened

  • zacks.com

    NVZMY vs. HWKN: Which Stock Is the Better Value Option?

  • defenseworld.net

    Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

  • zacks.com

    KROS or NVZMY: Which Is the Better Value Stock Right Now?

  • seekingalpha.com

    Novozymes A/S (NVZMY) Q3 2025 Earnings Call Transcript

  • zacks.com

    KMDA vs. NVZMY: Which Stock Is the Better Value Option?

  • seekingalpha.com

    Novonesis A/S (NVZMF) Q2 2025 Earnings Call Transcript

  • zacks.com

    Novozymes (NVZMY) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

  • seekingalpha.com

    Novonesis: Industry Leader With Defensive Characteristics And Solid Growth